Navigation Links
Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
Date:2/7/2008

CEDAR KNOLLS, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen(R) technology was 15-30 times greater than with the same dose of oral vitamin B12 administered alone. Emisphere's eligen(R) technology is the basis of the company's unique and improved delivery of therapeutic molecules and pharmaceutical compounds.

"This data demonstrates an exciting potential commercial avenue for our technology that can have a positive impact on the lives of many patients and Emisphere," said Michael V. Novinski, President and Chief Executive Officer of Emisphere.

There are at least five million people in the United States receiving 40 million B12 injections annually to treat a variety of debilitating medical conditions, and at least an additional five million people are consuming over 600 million tablets of B12 of various strengths annually. "We believe that the 40 million injections demonstrates an unmet need for an oral B12 preparation that can deliver therapeutic levels of B12 and that the megadoses being consumed as tablets are further evidence of this need," Novinski added.

The company's current timeline includes conducting clinical human trials beginning in the third quarter of 2008.

This information, and Emisphere's evolving business strategy, will be discussed during a conference call today at 10:00AM EST. The live conference call dial-in number is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International). An audio replay of the call will be available following the conference call by calling 1-888-203-1112 (U.S. and Canada) or 1-719-457-0820 (International). The conference replay PIN is 871428. A slide deck will be available on the Emisphere web site at the time of the call.

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen(R) technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The web site is: http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758), for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758), and for the quarter ended September 30, 2007, filed on November 6, 2007 (000-17758).


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
4. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. Senesco Technologies Initiates Preclinical Studies for Cancer Target
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 According ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Field Strength (High Field, Very High Field, Low to ... Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic and ... magnetic resonance imaging (MRI) market was valued at $5,351.7 ...
(Date:5/3/2016)... 3, 2016 Norgine ... sie einen entscheidenden Meilenstein durch diese Veröffentlichung ... zum Handeln, um Patientenresultate  bei Verdauungs- und ... Fortschritten im Verständnis der Hepatischen Enzephalopathie bei ... für Hepatische Enzephalopathie in der Öffentlichkeit zu ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... today announced data from the first cohort of ... trial (the OVATION Study) combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  In the first three patients ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ankle ... falls, or traffic accidents can cause the talus bone to be fractured, and a ... In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... announces the Everlasting Glove, a sports invention that aids in the improvement of ... Manufacturing industry is worth $9 billion," says Scott Cooper, CEO and Creative Director ...
(Date:5/4/2016)... ... 2016 , ... Trinity Health today launched its inaugural Innovation ... at improving care and reducing readmission rates for patients who are dually eligible ... is to drive innovation that transforms our ministry and our industry to be ...
(Date:5/4/2016)... AZ (PRWEB) , ... May 04, 2016 , ... ... Annual Technology & Business Conference. The conference opened on Tuesday with Frank Luntz, ... discussion on NCPDP’s PDMP Solution provided a deep dive on NCPDP’s model solution ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Level 10 Head ... her verbal commitment to the University of Arizona for the fall of 2019. ... decision last month. Brovedani’s commitment to the GymCats came from her connection with the ...
Breaking Medicine News(10 mins):